featured
Adding Anthracyclines to the Adjuvant Treatment of Breast Cancer: Data Review and Practical Implications
Interview by
Interview with
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- Blum JL, Flynn PJ, Yothers G, et al. Interim joint analysis of the ABC (anthracyclines in early breast cancer) phase III trials (USOR 06-090, NSABP B-46I/USOR 07132, NSABP B-49 [NRG Oncology]) comparing docetaxel + cyclophosphamide (TC) v anthracycline/taxane-based chemotherapy regimens (TaxAC) in women with high-risk, HER2-negative breast cancer. Paper presented at: 2016 Annual Meeting of the American Society of Clinical Oncology; June 3-7, 2016; Chicago, IL. Abstract 1000.
-
Piccart M, Rutgers E, van’t Veer L, et al. Primary analysis of the EORTC 10041/ BIG 3-04 MINDACT study: a prospective, randomized study evaluating the clinical utility of the 70-gene signature (MammaPrint) combined with common clinical-pathological criteria for selection of patients for adjuvant chemotherapy in breast cancer with 0 to 3 positive nodes. Paper presented at: 2016 American Association of Cancer Research Annual Meeting 2016; April 16-20, 2016; New Orleans, LA. Abstract CT039.
- Schwaederle MC, Zhao MM, Lee JJ, et al. Impact of precision medicine in refractory malignancies: A meta-analysis of 13,203 patients in phase I clinical trials. Paper presented at: 2016 Annual Meeting of the American Society of Clinical Oncology; June 3-7, 2016; Chicago, IL. Abstract 11520.
Disclosure statements are available on the authors' profiles: